FORWARD I (GOG 3011): A randomized phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian cancer (EOC), primary peritoneal cancer, or primary fallopian tube cancer.

Kathleen N. Moore,Ignace Vergote,Ana Oaknin,Nicoletta Colombo,Susana Banerjee,Amit M. Oza,Patricia Pautier,Catherine M. Kelly,Karim Malek,Rodrigo Ruiz-Soto,Michael J. Birrer

FORWARD I (GOG 3011): A randomized phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus chemotherapy in adults with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian cancer (EOC), primary peritoneal cancer, or primary fallopian tube cancer.

2017

Kathleen N. Moore
Ignace Vergote
Ana Oaknin
Nicoletta Colombo
Susana Banerjee
Amit M. Oza
Patricia Pautier
Catherine M. Kelly
Karim Malek
Rodrigo Ruiz-Soto
Michael J. Birrer

TPS5607Background: Elevated FRα expression is characteristic of a number of solid tumors, including EOC, thereby providing an attractive candidate for targeted therapeutic approaches. Mirvetuximab ...

Keywords:

Ovarian cancer
Folate Receptor Alpha
Fallopian tube cancer
Phases of clinical research
Oncology
Pathology
MIRVETUXIMAB SORAVTANSINE
Peritoneal cancer
Internal medicine
Medicine
Chemotherapy
platinum resistant
Cancer research
epithelial ovarian cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations